OncLive TV

Gary K. Schwartz, MD, discusses results of the Alliance A091401 trial (NCT02500797) in patients with metastatic sarcoma.

Bruno Sangro, MD, PhD, discusses the updated findings from the phase 3 CheckMate-459 trial, which evaluated the use of nivolumab and sorafenib in the treatment of patients with advanced hepatocellular carcinoma.

Jia Ruan, MD, PhD, discusses ​the utility of molecular profiling in mantle cell lymphoma.

Gaël Roué, PhD, discusses the synergistic activity with TG-1701, ublituximab, and umbralisib in ibrutinib-resistant mantle cell lymphoma models.

Huma Q. Rana, MD, MPH, discusses the prevalence of pathogenic variants in patients with prostate cancer enrolled on the ProGen study.

Caitlin Costello, MD, discusses the role of daratumumab in multiple myeloma.

Nikhil C. Munshi, MD, discusses the role of CAR T-cell therapy in relapsed/refractory multiple myeloma.

Shaji K. Kumar, MD, discusses stem cell mobilization multiple myeloma.

Katja Weisel, MD, discusses the safety profile of isatuximab-irfc in combination with carfilzomib, lenalidomide, and dexamethasone in high-risk patients with newly diagnosed multiple myeloma.

C. Ola Landgren, MD, PhD, discusses investigational cellular therapies in multiple myeloma.

Luciano J. Costa, MD, PhD, sheds light on CC-93269, a BCMA 2+1 T-cell engager, under examination in a phase 1 dose-finding study in relapsed/refractory multiple myeloma.

Caron Jacobson, MD, discusses the next steps with axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma.

Manfred Welslau, MD, discusses the rationale for investigating the Sandoz rituximab biosimilar, Rixathon, in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in diffuse large B-cell lymphoma.

Sattva Neelapu, MD, discusses the safety profile of ALLO-501 in combination with ALLO-647 in patients with relapsed/refractory large B-cell lymphoma or follicular lymphoma.

Fred Saad, MD, FRCS, discusses unanswered questions from the randomized phase 3 SPARTAN trial in nonmetastatic castration-resistant prostate cancer.

Noopur Raje, MD, discusses the rationale for CAR T-cell therapy in multiple myeloma.

María-Victoria Mateos, MD, PhD, discusses the significance of the ongoing phase 3 CANOVA trial, which is examining venetoclax in patients with relapsed/refractory t(11;14) multiple myeloma.

Alexandra Sokolova, MD, discusses the rationale for ​systematic germline testing in patients with metastatic prostate cancer.

Neeraj Agarwal, MD, discusses the results from the cohort 6 analysis of the COSMIC-021 trial in patients with metastatic castration-resistant prostate cancer​.

Michael Wang, MD, discusses the efficacy of KTE-X19 in low- and high-risk patients with relapsed/refractory mantle cell lymphoma as part of the phase 2 ZUMA-2 trial.

Caitlin Costello, MD, discusses proper dosing of carfilzomib in relapsed/refractory multiple myeloma.

Kim Chi, MD, discusses the utility of liquid biopsy in prostate cancer.

William K. Kelly, DO, discusses the next steps with the combination of radium-223 dichloride and niraparib in metastatic castration-resistant prostate cancer.

Paul G. Richardson, MD, discusses the next steps ​with the investigational cereblon E3 ligase modulator agent CC-92480 research in ​relapsed/refractory multiple myeloma.

Courtney DiNardo, MD, MSCE, discusses the rational​e for a pooled analysis evaluating venetoclax in acute myeloid leukemia.

Fred Saad, MD, FRCS, discusses unique characteristics of apalutamide compared with other antiandrogen agents in nonmetastatic castration-resistant prostate cancer.

Jeff P. Sharman, MD, discusses the challenges of adjusting treatments based on minimal residual disease status in high-risk chronic lymphocytic leukemia.

John Kuruvilla, MD, FRCPC, discusses the safety of pembrolizumab (Keytruda) versus brentuximab vedotin in classical Hodgkin lymphoma.

Jesus G. Berdeja, MD, discusses next steps for the phase 2 CARTITUDE-1 study with JNJ-4528 in relapsed/refractory myeloma.

Rana R. McKay, MD, discusses the design of the phase 3 PDIGREE study in advanced renal cell carcinoma.